Get the Weekly Intelligence Brief — top committee picks every Sunday.
SNN · NYSE · STOCK

Smith & Nephew plc

Healthcare Updated August 11, 2026
$30.05
52W $28.56 – $38.79
59/100
$12.60B
19.7
0.69
AI Committee Verdict
Watch
59/100
Conviction: Contested · 40% agreement · 5 analysts
Contested

Is SNN Bullish or Bearish?

Mixed. Innellis AI committee rates Smith & Nephew plc (SNN) Watch with a composite score of 59/100 , based on 5 analysts with 40% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +1.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -18.75 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Technical Analyst remains cautious — price structure making lower highs and lower lows. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 2.7% pays you to wait — Value
  • EPS growing 52.3% YoY — Growth
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price structure making lower highs and lower lows — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Trend and market structure agree -- coherent bearish picture — Technical
  • Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
59/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 56%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 2.7% pays you to wait
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ EPS growing 52.3% YoY
Technical Analyst bearish
39 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
40.7
Neutral
MACD Histogram
-0.185
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$29.09
Resistance
$31.40
Bollinger %B
0.29
Inside Bands
Price vs Moving Averages
EMA 9
$30.48 Below
EMA 21
$30.65 Below
EMA 50
$30.70 Below
EMA 200
$31.70 Below

Fundamental Analysis

Valuation
89
Profitability
67
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio 19.7×
P/B Ratio 2.44×
PEG Ratio 0.59
Dividend Yield 2.62%
52W High $38.79
52W Low $28.56
Quality & Growth
ROE 1181.7%
ROA 597.7%
Gross Margin 6818.1%
Operating Margin 1668.8%
Revenue Growth YoY
Debt / Equity 0.73
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 19.7 (inexpensive relative to a 15-40x range); Price-to-book of 2.4x; PEG ratio of 0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.8%; Return on assets of 6.0%; Net margin of 10.1%; Gross margin of 68.2%; Current ratio of 2.14 (healthy short-term liquidity); Debt-to-equity of 0.73; Free cash flow per share is positive (2.00); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full SNN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore SNN Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime